Summary: Inspire Medical Systems, a company specializing in minimally invasive solutions for obstructive sleep apnea, announced the approval of reimbursement for its Inspire therapy in France. The therapy, which received European Conformity Marking in 2010, has already secured reimbursement in several key European countries, enhancing its market opportunity in the second-largest OSA market in Europe.
Three Key Takeaways:
- Reimbursement Approval in France: Inspire therapy for OSA has received reimbursement approval from the French Social Security, expanding its availability to a larger patient population in France.
- Clinical Validation: Inspire therapy is backed by clinical evidence, demonstrating its safety and efficacy for treating moderate to severe OSA.
- Market Expansion: With the reimbursement approval in France, Inspire Medical Systems strengthens its presence in Europe, targeting key markets to enhance its commercial efforts and reach more patients.
Inspire Medical Systems, a medical technology company focused on the development of minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced the publication of the reimbursement of Inspire therapy in France.
“We are thrilled to offer our clinically proven treatment option for moderate to severe OSA to patients and physicians in France,” says Tim Herbert, chairman and chief executive officer of Inspire, in a release. “Inspire therapy is backed by a strong body of evidence and years of clinical experience demonstrating the safety and efficacy of our therapy.”
Inspire therapy received European Conformity Marking for commercialization in Europe in 2010. Since that time, the company’s approach has been to secure reimbursement in targeted countries prior to commencing commercialization efforts. Inspire has already established reimbursement in many key European countries, and the addition of full reimbursement in France expands the market opportunity as France is the second-largest OSA market in Europe.
The approval in France provides reimbursement consistent with other European and global markets.
“Thanks to the reimbursement of Inspire therapy by the French Social Security, sleep physicians now have a new therapeutic option for patients with untreated OSA,” says Andreas Henke, executive vice president and managing director, Europe, in a release.
Photo 72117166 © Sjankauskas | Dreamstime.com
Leave a Reply